Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 682

Sort by

Sort Order Select

Journal Articles

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Blood (2020) 136 (1): 71–80.

https://doi.org/10.1182/blood.2019004460

Published: 2020

Includes: Supplemental data

Journal Articles

Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study

Vaishali Sanchorawala, Shayna Sarosiek, Amanda Schulman, Meredith Mistark, Mary Ellen Migre, Ramon Cruz, J. Mark Sloan, Dina Brauneis, Anthony C. Shelton

Blood (2020) 135 (18): 1541–1547.

https://doi.org/10.1182/blood.2019004436

Published: 2020

Journal Articles

A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis

Blood (2020) 135 (18): 1531–1540.

https://doi.org/10.1182/blood.2019004369

Published: 2020

Includes: Supplemental data

Journal Articles

Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria

Christoph R. Kimmich, Tobias Terzer, Axel Benner, Tobias Dittrich, Kaya Veelken, Alexander Carpinteiro, Timon Hansen, Hartmut Goldschmidt, Anja Seckinger, Dirk Hose, Anna Jauch, Stefan Wörner, Jörg Beimler, Carsten Müller-Tidow, Ute Hegenbart, Stefan O. Schönland

Blood (2020) 135 (18): 1517–1530.

https://doi.org/10.1182/blood.2019003633

Published: 2020

Includes: Supplemental data

Journal Articles

Sanchorawala V, Palladini G, Kukreti V, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130(5):597-605.

Blood (2020) 135 (13): 1071.

https://doi.org/10.1182/blood.2020005086

Published: 2020

Journal Articles

Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis

Marco Basset, Irene Defrancesco, Paolo Milani, Mario Nuvolone, Sara Rattotti, Andrea Foli, Silvia Mangiacavalli, Marzia Varettoni, Pietro Benvenuti, Claudio Salvatore Cartia, Marco Paulli, Giampaolo Merlini, Luca Arcaini, Giovanni Palladini

Blood (2020) 135 (4): 293–296.

https://doi.org/10.1182/blood.2019002762

Published: 2020

Journal Articles

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib

Richa Manwani, Oliver Cohen, Faye Sharpley, Shameem Mahmood, Sajitha Sachchithanantham, Darren Foard, Helen J. Lachmann, Cristina Quarta, Marianna Fontana, Julian D. Gillmore, Carol Whelan, Philip N. Hawkins, Ashutosh D. Wechalekar

Blood (2019) 134 (25): 2271–2280.

https://doi.org/10.1182/blood.2019000834

Published: 2019

Journal Articles

Similar Survival with Deferred Versus Salvage Autologous Stem Cell Transplant in Light Chain Amyloidosis

Danny Luan, BS, MPH, Koen Van Besien, MD PhD, Paul J Christos, Dr.P.H., M.S., Roger Pearse, MD PhD, Danielle Guarneri, BS, CCRP, Morton Coleman, MD, Ruben Niesvizky, MD, Cara A. Rosenbaum, MD

Blood (2019) 134 (Supplement_1): 4579.

https://doi.org/10.1182/blood-2019-127723

Published: 2019

Journal Articles

In Systemic Light-Chain Amyloidosis Complete and Very Good Partial Responses Are Not Enough: Involved Free Light Chain (iFLC) Levels < 10mg/L Are Associated with Optimal Long-Term Survival

Amandeep Godara, MD, Denis Toskic, BS, Benjamin Rosenthal, BS, Cindy Varga, MD BSc, Adin Kugelmass, BSc, Ping Zhou, MD PhD, Teresa Fogaren, NP, Raymond L Comenzo, MD

Blood (2019) 134 (Supplement_1): 4369.

https://doi.org/10.1182/blood-2019-127004

Published: 2019

Journal Articles

Difference in Involved and Uninvolved Free Light Chain (dFLC) of Less Than 1mg/DL Early Post Risk Adapted Melphalan and Autologous Stem Cell Transplantation (RA-ASCT) Predicts Renal Response at 1 Year in Light Chain (AL) Amyloidosis

Sneha Purvey, MD, Kenneth Seier, MS, Sean M. Devlin, PhD, Josel D Ruiz, MPH, Molly A. Maloy, MS, Gunjan L. Shah, MDMS, Hani Hassoun, MD, Sergio A. Giralt, MD, Heather J Landau, MD

Blood (2019) 134 (Supplement_1): 4577.

https://doi.org/10.1182/blood-2019-129195

Published: 2019

Journal Articles

Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study

Shayna Sarosiek, John Mark Sloan, MD, Karen Quillen, MDMPH, Dina Brauneis, ANP, Ramon Cruz, Amanda Schulman, Salli Fennessey, Anthony Shelton, Vaishali Sanchorawala, MD

Blood (2019) 134 (Supplement_1): 4578.

https://doi.org/10.1182/blood-2019-129095

Published: 2019

Journal Articles

Quantitative Immunoprecipitation Free Light Chain Mass Spectrometry (QIP-FLC-MS) Simplifies Monoclonal Protein Assessment and Provides Added Clinical Value in Systemic AL Amyloidosis

Faye Amelia Sharpley, BA MA MSc MBBChir FRCPath, Hannah Victoria Giles, FRCPath, MRCP, Richa Manwani, MBBS, FRCPath, BSc, Shameem Mahmood, Sajitha Sachchithanantham, Helen J Lachmann, MA MB BChir MDFRCP, Julian D Gillmore, MBBS, MD PhD FRCP, Carol J Whelan, Philip N Hawkins, Ashutosh D Wechalekar, MB BS, MD FRCP, FRCPath, DM

Blood (2019) 134 (Supplement_1): 4375.

https://doi.org/10.1182/blood-2019-128175

Published: 2019

Journal Articles

Prediction of Malingant Plasma Cell Biology Related Survival in AL-Amyloidosis

Susanne Beck, Martina Emde, Jerome Moreaux, PhD, Anja Seckinger, Dirk Hose, MD

Blood (2019) 134 (Supplement_1): 3078.

https://doi.org/10.1182/blood-2019-131161

Published: 2019

Journal Articles

Preliminary Phase 1 Data on the Safety and Efficacy of a Novel PET Radiotracer, 124 I-p5+14, for Imaging Systemic Amyloidosis

Blood (2019) 134 (Supplement_1): 3034.

https://doi.org/10.1182/blood-2019-128850

Published: 2019

Journal Articles

In Vitro and in Vivo Activity of Melflufen in Amyloidosis

Ken Flanagan, PhD, Muntasir M Majumder, MSc, BPharm, Romika Kumari, PhD, Juho Miettinen, PhD, Ana Slipicevic, PhD, Sarah A. Holstein, MD PhD, Michelle L. Varney, MS, Minna Suvela, MSC, Fredrik Lehmann, PhD, Nina N. Nupponen, PhD, Caroline A Heckman, PhD

Blood (2019) 134 (Supplement_1): 3100.

https://doi.org/10.1182/blood-2019-125952

Published: 2019

Journal Articles

Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant

M Hasib Sidiqi, MBBS, Abdullah S. S. Al Saleh, MBBS, Iuliana Vaxman, MDBA, Angela Dispenzieri, MD, Francis K. Buadi, MB, CHB, Eli Muchtar, MD, Rahma M Warsame, MD, Martha Q. Lacy, MD, David Dingli, MD PhD, Nelson Leung, MD, Wilson I Gonsalves, MD, Prashant Kapoor, MD, Taxiarchis Kourelis, MD, S. Vincent Rajkumar, MD, Shaji K. Kumar, MD, Morie A Gertz, MD

Blood (2019) 134 (Supplement_1): 3171.

https://doi.org/10.1182/blood-2019-125453

Published: 2019

Journal Articles

Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients

Morie A Gertz, MD, Adam D. Cohen, MD, Raymond L Comenzo, MD, Charles Du Mond, Eftathios Kastritis, Heather J Landau, MD, Edward N. Libby, III, MD, Michaela Liedtke, MD, Giampaolo Merlini, MD, Vaishali Sanchorawala, MD, Stefan O. Schönland, MD, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM, Jeffrey A. Zonder, Gene Kinney, PhD

Blood (2019) 134 (Supplement_1): 3166.

https://doi.org/10.1182/blood-2019-124482

Published: 2019

Journal Articles

Firstline Daratumumab Shows High Hematologic and Organ Response Rates in Advanced Cardiac AL Amyloidosis - a Retrospective Case Series

Georg Jeryczynski, MD, Antonia Eder, Eva-Maria Reitter, MD, Maria-Theresa Krauth, MD, Hermine Agis, MD

Blood (2019) 134 (Supplement_1): 3123.

https://doi.org/10.1182/blood-2019-124681

Published: 2019

Journal Articles

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Is a Renal Biomarker with Potential Clinical Applications in Monoclonal Gammopathy of Renal Significance (MGRS)

Eftathios Kastritis, Ioannis Papassotiriou, PhD, Maria Roussou, MD, Maria Gavriatopoulou, MD, Mantzou Aimilia, PhD, Erasmia Psimenou, MD, Smaragdi Marinaki, Charikleia Gakiopoulou, MD, Alexandra Margeli, PhD, Nikolaos Kanellias, MD, Magdalini Migkou, MD, Despina Fotiou, BMBS, MA, Ioannis Ntanasis-Stathopoulos, MD, Gerasimos-Petros Papassotiriou, PhD, Aristea-Maria Papanota, MD, Evangelos Terpos, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 3126.

https://doi.org/10.1182/blood-2019-125305

Published: 2019

Journal Articles

A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloidosis

Larysa Sanchez, MD, Heather J Landau, MD, Cara A. Rosenbaum, MD, Alex Abrahams, Cindy Chin, Brielle Liotta, BS, Natalie Agudo, RN, Sheetal Ramnath, Elizabeth Hoover, BS, Hafsa Rahman, Umut Ozbek, PhD, Oscar B Lahoud, MD, Hani Hassoun, MD, Keren Osman, MD

Blood (2019) 134 (Supplement_1): 3128.

https://doi.org/10.1182/blood-2019-126023

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study

A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis

Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria

Sanchorawala V, Palladini G, Kukreti V, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130(5):597-605.

Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib

Similar Survival with Deferred Versus Salvage Autologous Stem Cell Transplant in Light Chain Amyloidosis

In Systemic Light-Chain Amyloidosis Complete and Very Good Partial Responses Are Not Enough: Involved Free Light Chain (iFLC) Levels < 10mg/L Are Associated with Optimal Long-Term Survival

Difference in Involved and Uninvolved Free Light Chain (dFLC) of Less Than 1mg/DL Early Post Risk Adapted Melphalan and Autologous Stem Cell Transplantation (RA-ASCT) Predicts Renal Response at 1 Year in Light Chain (AL) Amyloidosis

Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study

Quantitative Immunoprecipitation Free Light Chain Mass Spectrometry (QIP-FLC-MS) Simplifies Monoclonal Protein Assessment and Provides Added Clinical Value in Systemic AL Amyloidosis

Prediction of Malingant Plasma Cell Biology Related Survival in AL-Amyloidosis

Preliminary Phase 1 Data on the Safety and Efficacy of a Novel PET Radiotracer, 124 I-p5+14, for Imaging Systemic Amyloidosis

In Vitro and in Vivo Activity of Melflufen in Amyloidosis

Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant

Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients

Firstline Daratumumab Shows High Hematologic and Organ Response Rates in Advanced Cardiac AL Amyloidosis - a Retrospective Case Series

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Is a Renal Biomarker with Potential Clinical Applications in Monoclonal Gammopathy of Renal Significance (MGRS)

A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only